Back to Search Start Over

Neonatal Diabetes Mellitus.

Authors :
Beltrand J
Busiah K
Vaivre-Douret L
Fauret AL
Berdugo M
Cavé H
Polak M
Source :
Frontiers in pediatrics [Front Pediatr] 2020 Sep 30; Vol. 8, pp. 540718. Date of Electronic Publication: 2020 Sep 30 (Print Publication: 2020).
Publication Year :
2020

Abstract

Neonatal Diabetes (ND) mellitus is a rare genetic disease (1 in 90,000 live births). It is defined by the presence of severe hyperglycaemia associated with insufficient or no circulating insulin, occurring mainly before 6 months of age and rarely between 6 months and 1 year. Such hyperglycaemia requires either transient treatment with insulin in about half of cases, or permanent insulin treatment. The disease is explained by two major groups of mechanism: malformation of the pancreas with altered insulin-secreting cells development/survival or abnormal function of the existing pancreatic β cell. The most frequent genetic causes of neonatal diabetes mellitus with abnormal β cell function are abnormalities of the 6q24 locus and mutations of the ABCC8 or KCNJ11 genes coding for the potassium channel in the pancreatic β cell. Other genes are associated with pancreas malformation or insufficient β cells development or destruction of β cells. Clinically, compared to patients with an ABCC8 or KCNJ11 mutation, patients with a 6q24 abnormality have lower birth weight and height, are younger at diagnosis and remission, and have a higher malformation frequency. Patients with an ABCC8 or KCNJ11 mutation have neurological and neuropsychological disorders in all those tested carefully. Up to 86% of patients who go into remission have recurrent diabetes when they reach puberty, with no difference due to the genetic origin. All these results reinforce the importance of prolonged follow-up by a multidisciplinary pediatric team, and later doctors specializing in adult medicine. 90% of the patients with an ABCC8 or KCNJ11 mutation as well as those with 6q24 anomalies are amenable to a successful switch from insulin injection to oral sulfonylureas.<br /> (Copyright © 2020 Beltrand, Busiah, Vaivre-Douret, Fauret, Berdugo, Cavé and Polak.)

Details

Language :
English
ISSN :
2296-2360
Volume :
8
Database :
MEDLINE
Journal :
Frontiers in pediatrics
Publication Type :
Academic Journal
Accession number :
33102403
Full Text :
https://doi.org/10.3389/fped.2020.540718